Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients

被引:3
|
作者
Tong, Yiwei [1 ]
Huang, Jiahui [1 ]
Ren, Weili [2 ]
Yu, Jing [1 ]
Zhang, Xu [1 ]
Wang, Zheng [1 ]
Hong, Jin [1 ]
Gao, Weiqi [1 ]
Wu, Jiayi [1 ]
Ji, Min [3 ]
Shen, Kunwei [1 ]
Chen, Xiaosong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China
[2] Shaoxing Shangyu Peoples Hosp, Dept Breast Surg, Shaoxing 312300, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Int Peace Matern & Child Hlth Hosp, Dept Breast, Sch Med, 910 Hengshan Rd, Shanghai 200030, Peoples R China
基金
中国国家自然科学基金;
关键词
Breast cancer; Tumor immune microenvironment; Immune profiling; 21-gene recurrence score; Prognosis; INTERNATIONAL EXPERT CONSENSUS; INFILTRATING LYMPHOCYTES; PRIMARY THERAPY; DUCTAL CARCINOMA; PROGNOSTIC VALUE; HIGHLIGHTS; ADJUVANT; PROPOSAL; TRIALS;
D O I
10.1186/s40001-022-00917-3
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Tumor immune microenvironment (TIME) plays a vital role in breast cancer development, treatment resistance, and prognosis. This study evaluates the association of TIME profiling and 21-gene recurrence score (RS) in early Luminal breast cancer patients.Methods: ER+ /HER2-, pN0 breast cancer patients with available RS results who received surgery between January 2009 and December 2013 were enrolled. TIME markers, including stromal tumor infiltrating lymphocytes (TILs), CD3, CD4, CD8, and tumor PD-L1 expression, were comprehensively analyzed. Association of TIME markers with RS, as well as their correlation with breast cancer-specific survival (BCSS) were tested.Results: Overall, 385 patients were included, of whom 341 (88.6%) had TILs <= 10%. TIME markers were positively but moderately correlated with each other (Spearman r 0.28-0.53, all P < 0.05). Continuous RS showed a weak correlation with continuous TILs, CD3, CD8, and PD-L1. Regarding single gene mRNA level in the 21-gene RS panel, higher expression of TIME markers was related to lower ER group genes expression, but higher proliferation and invasion group genes level. After a median follow-up of 91.67 (range 5.03-134.03) months, TILs (P = 0.049) and PD-L1 (P = 0.034) were inversely associated with BCSS.Conclusions: Breast cancer TIME markers, including TILs, CD3, CD4, CD8, and PD-L1, were correlated with 21-gene RS score. Lower expression of ER group genes, as well as higher expression of proliferation and invasion group genes were associated with a higher level of these TIME markers, warranting further exploration.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score
    Andreas D. Hartkopf
    Markus Wallwiener
    Stefan Kommoss
    Florin-Andrei Taran
    Sara Y. Brucker
    Breast Cancer Research and Treatment, 2016, 156 : 91 - 95
  • [22] Detection of disseminated tumor cells from the bone marrow of patients with early breast cancer is associated with high 21-gene recurrence score
    Hartkopf, Andreas D.
    Wallwiener, Markus
    Kommoss, Stefan
    Taran, Florin-Andrei
    Brucker, Sara Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (01) : 91 - 95
  • [23] The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment
    Ethier, Josee-Lyne
    Amir, Eitan
    MOLECULAR DIAGNOSIS & THERAPY, 2016, 20 (04) : 307 - 313
  • [24] The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients
    Li, Yun
    Kurian, Allison W.
    Bondarenko, Irina
    Taylor, Jeremy M. G.
    Jagsi, Reshma
    Ward, Kevin C.
    Hamilton, Ann S.
    Katz, Steven J.
    Hofer, Timothy P.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (03) : 587 - 595
  • [25] Impact of the 21-gene recurrence score assay in adjuvant chemotherapy selection for node-negative, hormone receptor-positive breast cancer in the Chinese population
    Zhang, Y. N.
    Zhou, Y. D.
    Mao, F.
    Sun, Q.
    NEOPLASMA, 2015, 62 (04) : 658 - 665
  • [26] The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients
    Yun Li
    Allison W. Kurian
    Irina Bondarenko
    Jeremy M. G. Taylor
    Reshma Jagsi
    Kevin C. Ward
    Ann S. Hamilton
    Steven J. Katz
    Timothy P. Hofer
    Breast Cancer Research and Treatment, 2017, 161 : 587 - 595
  • [27] Ki-67 and 21-gene recurrence score assay in decision making for adjuvant chemotherapy in breast cancer patients
    Mohammad Aghebati
    Reza Hossieni
    Afsaneh Sadat Makeh
    Alireza Shirzadi
    Mohammad Esmaeil Akbari
    Discover Oncology, 16 (1)
  • [28] Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients
    Peng Qi
    Yu Yang
    Qian-ming Bai
    Tian Xue
    Min Ren
    Qian-lan Yao
    Wen-tao Yang
    Xiao-yan Zhou
    Breast Cancer Research and Treatment, 2021, 186 : 327 - 342
  • [29] The Tumor Immune Microenvironment in Breast Cancer Progression
    Fjortoft, Marit Otterlei
    Huse, Kanutte
    Rye, Inga Hansine
    ACTA ONCOLOGICA, 2024, 63 : 359 - 367
  • [30] Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study
    Zeng, Yinduo
    Li, Qian
    Qin, Tao
    Li, Shunrong
    Jin, Liang
    Wu, Jiannan
    Chen, Kai
    Deng, Heran
    Rao, Nanyan
    Liu, Qiang
    Su, Fengxi
    Jia, Weijuan
    Yao, Herui
    ANTICANCER RESEARCH, 2017, 37 (08) : 4539 - 4547